A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma
- 12 February 2021
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (8), 2123-2125
- https://doi.org/10.1158/1078-0432.ccr-21-0140
Abstract
Drugs that target Bruton's tyrosine kinase (BTK) have been highly successful and changed the landscape of therapies in B-cell lymphomas. However, their lower rates of effectiveness in follicular lymphoma are unexplained. Recent work describes inactivating BTK mutations which show that at least some follicular lymphomas don't require BTK.Keywords
Funding Information
- NIH NCI (1K08CA230319)
This publication has 5 references indexed in Scilit:
- Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT ActivationClinical Cancer Research, 2021
- Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyJournal of Clinical Oncology, 2018
- Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphomaBlood, 2017
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibThe New England Journal of Medicine, 2014
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent LymphomaThe New England Journal of Medicine, 2014